SCHEMBL5410396

SCHEMBL5410396

CNc1nc(Nc2ccc(C)c(C)c2)ncc1[N+](=O)[O-]

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 3/20 0.55
▸ KMT2A Q03164 5/20 0.55
▸ MEN1 O00255 4/20 0.55
▸ MAPT P10636 3/20 0.55
▸ CYP1A2 P05177 1/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ CYP2C19 P33261 1/20 0.55
▸ MCL1 Q07820 1/20 0.55
▸ PTK2B Q14289 1/20 0.55
▸ ALDH1A1 P00352 3/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ AURKA O14965 2/20 0.50
▸ GSK3A P49840 2/20 0.50
▸ STK17A Q9UEE5 3/20 0.48
▸ BTK Q06187 2/20 0.47
▸ NPC1 O15118 2/20 0.46
▸ BRD4 O60885 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5413733 0.89 MEN1 (0.54) GSK3BKMT2AMEN1MAPTCYP1A2
SCHEMBL5419368 0.86 GSK3B (0.63) GSK3BKMT2AMEN1MAPTCYP1A2
SCHEMBL5408207 0.85 GSK3B (0.61) GSK3BKMT2AMEN1MAPTCYP1A2
SCHEMBL5425765 0.84 GSK3B (0.61) GSK3BKMT2AMEN1MAPTCYP1A2
SCHEMBL5410032 0.84 GSK3B (0.54) GSK3BKMT2AMEN1MAPTCYP1A2
SCHEMBL5414030 0.84 GSK3B (0.54) GSK3BKMT2AMEN1MAPTCYP1A2
SCHEMBL5419878 0.84 GSK3B (0.61) GSK3BKMT2AMEN1MAPTCYP1A2
SCHEMBL5408180 0.82 STK17A (0.66) GSK3BKMT2AMEN1MAPTCYP1A2
SCHEMBL5405521 0.82 GSK3B (0.61) GSK3BKMT2AMEN1MAPTCYP1A2
SCHEMBL5402419 0.82 MAPT (0.62) GSK3BKMT2AMEN1MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US disclosed
EP-1453516-A2 NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-09-08 — — EP disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US disclosed
WO-2003032994-A2 NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-04-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 GSK3B 1515/4885KMT2A 4026/4885MEN1 3119/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 GSK3B 790/4885KMT2A 4480/4885MEN1 2729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback